Followers | 17 |
Posts | 936 |
Boards Moderated | 0 |
Alias Born | 04/26/2010 |
Monday, September 07, 2020 4:11:42 PM
I have, or better said, have tried to do some checking of Galera's claims found in the report from GC4419 PIIb trial for SOM. I got outright giddy when I noticed that they have included SOM incidence and duration swim-lane chart. Hah, nitwits are providing me the means to do thorough checking of ALL REPORTED VALUES. I should have known better.
Obvious sign of trouble besides missing headcounts in table 2 is that in the said table Galera reports median duration of SOM for GC4419 90 mg dose as 1.5 days. If you check the swim-lane chart you see that for 90 mg dose there is total 35 SOM incidents. Headcount for intent to treat group for 90 mg dose happens to be 76. How can one get SOM median 1.5 days when less than 50 % of subjects did ever experience it? Of course, one can't. More misery can be found in the statistical methods section:
So, even if the values in table 2 are for ITT, as they should be, they are after ‘imputation’ of missing values, which I obviously don’t have access to. At this point you should exclaim (Please, do exclaim. It would make me feel better knowing you did):
“WHAAAT! Is this proper, legit, does it cut the mustard!”
Unfortunately, it does. FDA uses similar methods, especially with heavily censored data, to estimate what might be more proper values. Then, if their findings do indicate so, they may tell the applicate: “Nice try, but no cigar this time.” If FDA can use a method to approve or reject drug application, they hardly can object to applicant using it. Also, it is approved and frequent practice in academic circles.
The above means that my grand analysis plan went the usual way, into garbage. But I can squeeze something out of those swim-lanes. They probably are for subjects for which Galera had complete SOM history, before applying what I call backfilling. That would mean, according to Galera, that they should cover about 80 % of trial subjects. That would be good enough. Unfortunately, it quickly became obvious, mostly comparing with figures 2 and A1 (in appendix) that swim-lanes probably are not completely accurate even for those subjects. Oh darn!
Finally, I decided to use values that looked the most reliable (very relative term, in this context): SOM grade > 2 and grade 4 start times. And applied the least sensitive measure I could on them, that is: I calculated risk ratios.
Log-Rank risk ratio for SOM grade 4 start times:
0.56 with 95 % confidence interval [0.3 , 1.08] favoring GC4419
Log-Rank risk ratio for SOM grade > 2 start times:
0.67 with 95 % confidence interval [0.42 , 1.04] favoring GC4419
Risk ratio for SOM grade 4 incidence rates during IMR treatment (first 7 weeks):
0.53 with Miettinen-Nurminen 95 % confidence interval [0.28 , 0.98]
The last one favors GC4419 quite strongly, confidence interval does not include 1. Other confidence intervals do.
About above results I trust more numbers for grade 4 SOM. Those subjects are less likely to be lost for follow-up. They tend to be in hospital bed and in IV. Another thing: I have found that risk ratio below 0.7 in relatively sized trials is quite good indicator for successful phase 3. Of course, it is not infallible, especially with Galera data here.
So, here you are. Just remember to treat my results as you would a rabid cat – with extreme caution.
BTW: a link to the article in question. In case you don’t have it handy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881100/
"I would rather have questions that can't be answered than answers that can't be questioned." Richard P. Feynman
Recent GRTX News
- Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates • GlobeNewswire Inc. • 03/28/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:06:04 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/20/2024 11:57:58 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 01/16/2024 11:11:39 PM
- Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates • GlobeNewswire Inc. • 11/14/2023 12:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 11/13/2023 07:24:56 PM
- Galera Shares Halted After FDA Says Avasopasem Needs Additional Phase 3 Trial • Dow Jones News • 10/31/2023 12:09:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 11:10:53 AM
- Galera Announces Receipt of Type A Meeting Minutes and Strategic Update • GlobeNewswire Inc. • 10/31/2023 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/26/2023 11:24:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2023 09:12:53 PM
- Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem • GlobeNewswire Inc. • 09/18/2023 11:00:00 AM
- Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/05/2023 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 11:30:36 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 11:10:28 AM
- Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates • GlobeNewswire Inc. • 08/14/2023 11:00:17 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/10/2023 12:00:58 PM
- Stocks to Watch: Applovin, Disney, Galera Therapeutics • Dow Jones News • 08/10/2023 12:10:00 AM
- Galera Therapeutics to Reduce Workforce by 70% to Extend Cash Runway • Dow Jones News • 08/09/2023 09:23:00 PM
- Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese • GlobeNewswire Inc. • 08/09/2023 08:31:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/05/2023 08:11:02 PM
- Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting • GlobeNewswire Inc. • 06/05/2023 06:15:00 PM
- Galera Therapeutics Gets Orphan Drug Designation for Rucosopasem • Dow Jones News • 05/18/2023 12:44:00 PM
- Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer • GlobeNewswire Inc. • 05/18/2023 12:00:00 PM
- Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates • GlobeNewswire Inc. • 05/11/2023 11:00:00 AM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM